ScreenerHero

AAPGAscentage Pharma Group International American Depository Shares

NAS · US · Healthcare · Biotechnology · ascentage.cn
17.00USDMkt Cap: 1.59B $P/E: —

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product can…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.59B $
Enterprise Value1.79B $
Revenue (TTM)642.64M $
Gross Profit525.18M $
Net Income (TTM)-1.24B $
Revenue/Share6.912 USD
Last Price17.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees767
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.62
PEG—
EV/EBITDA-1.34
EV/Revenue2.79
P/S2.47
P/B19.17
EPS (TTM)-2.35
EPS (Forward)-1.35
52W Range
17.000% of range17.44
52W High17.44 USD
52W Low17.00 USD
Profitability
Gross Margin91.48%
Oper. Margin-248.91%
EBITDA Margin-208.03%
Profit Margin-216.47%
ROE-93.83%
ROA-31.35%
Growth
Revenue Growth29.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.17B $
CapEx (TTM)27.57M $
FCF Margin-151.61%
FCF Yield-61.40%
Net Debt198.99M $
Net Debt/EBITDA-0.15
Balance Sheet
Debt/Equity1.49
Current Ratio1.22
Quick Ratio1.09
Book Value/Sh0.8868 USD
Cash/Share20.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.44 USD
Upside (mean)+179.1%
Target Range40.00 USD – 55.00 USD
$40.00+179.1% to mean$55.00
# Analysts9
Ownership
Shares Out.93.34M
Float71.48M
Insiders0.00%
Institutions0.04%
Short Interest
Short Ratio2.5d
Short % Float0.02%
Short % Out.0.02%
Shares Short15.74K
Short (prev mo.)158.02K
Technical
SMA 5018.19 (-6.5%)
SMA 20023.63 (-28.1%)
Beta—
S&P 52W Chg19.18%
Avg Vol (30d)1.73K
Avg Vol (10d)6.22K
Technical Indicators
RSI (14)37.9
MACD-0.2004
MACD Signal-0.0965
MACD Hist.-0.1039
BB Upper19.75 USD
BB Middle18.05 USD
BB Lower16.35 USD
BB Width18.82%
ATR (14)0.6793 USD
Vol Ratio (20d)0.29x